Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

IMA new masthead1

Internal Medicine Alert – December 30, 2014

December 30, 2014

View Archives Issues

  • Another Reason Why Sitting is Just No Darn Good For You

    Although not a life-threatening condition, benign prostatic hypertrophy (BPH) is one of the most annoying and troublesome problems that plagues aging males.
  • You Have Type I Diabetes ... Now The BAD News!

    Type 1 diabetes is associated with an increased risk of mortality, secondary to microvascular (neuropathy, nephropathy) and macrovascular (coronary artery disease, stroke, peripheral vascular disease) complications.
  • Peri-procedural Management of New Oral Anticoagulants

    Due to the short half-life and rapid onset of action of the new oral anticoagulants (NOACs), peri-procedural anticoagulant free time intervals should be shorter than with warfarin. Thus, there is uncertainty about the use of heparin bridging.
  • Aortic Prosthetic Valve Type and Survival

    Bioprosthetic aorta valves are recommended for those > 70 years of age because of their reduced durability compared to mechanical valves and mechanical prostheses, which are recommended for those < 60 years because bioprosthetic valves deteriorate more rapidly in younger individuals.
  • Hydrocodone Bitartrate Extended-release Tablets (Hysingla ER) CII

    Hydrocodone is formulated to resist crushing, breaking, and dissolution and still retain some extended-release properties.
  • Clinical Briefs

    Because of its strong efficacy, long-term durability, and predictability when titrated with algorithms employed in clinical trials, basal insulin remains a mainstay of treatment for type 2 diabetes patients who are not able to attain or maintain glycemic control with oral agents alone. Because diabetes is a progressive disorder, even patients who are initially well-controlled on basal insulin will likely require “fine tuning” of their diabetes regimen, usually with agents that preferentially affect postprandial glucose levels.